Fairvalue-Calculator Fairvalue-Calculator
EN DE

Micro-Tech (Nanjing) Co (688029) Fair Value & Analysis

Healthcare · CN · Market cap 13.8B CNY

Price¥68.48
Fair Value¥66.77
Upside-2.5%
Quality80/100
Evidence: Medium Range ¥50.08 – ¥83.46

Analysis

Micro-Tech (Nanjing) Co (688029) currently trades at ¥68.48, while our model-based Fair Value estimate is ¥66.77 — implying the stock looks roughly 2.5% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Micro-Tech (Nanjing) Co.,Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of invasive medical devices in China and internationally. The company offers digestive endoscopy products, including ESD, such as electric flushing device, harmony/GT gold clip, gold/titanium knife, pull clamp, three-arm clap, hemostatic titanium forceps, injection needle, vascular clamp, spray pipe, electric oil, and indigo carmine muscosal staining agent; and ERCP comprising biliary duct drainage tube, nasobiliary drainage catheter, stone removal balloon, stone retrieval basket, level 3 balloon dilation catheter, guide wire, ruyi knife, and eyemax insights. It also provides hemostasis, which includes bandage and star king clip; dilation and biopsy, such as covered biliary stent, biliary stent, intestinal stent kit with biopsy access, intestinal stent, covered intestinal stent, segmented esophageal stent system, and covered esophageal stent kit; EUS comprising…

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.